Market Research Logo

Thymic Carcinoma - Pipeline Review, H2 2016

Thymic Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thymic Carcinoma – Pipeline Review, H2 2016, provides an overview of the Thymic Carcinoma (Oncology) pipeline landscape.

Thymus cancers are uncommon cancers that start in the thymus. Symptoms include shortness of breath, cough, chest pain, trouble swallowing, loss of appetite, headaches and weight loss. Predisposing factor include age and other autoimmune diseases such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thymic Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thymic Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thymic Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thymic Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Thymic Carcinoma.

Thymic Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thymic Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Thymic Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thymic Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thymic Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thymic Carcinoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thymic Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thymic Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Thymic Carcinoma Overview
Therapeutics Development
Pipeline Products for Thymic Carcinoma - Overview
Pipeline Products for Thymic Carcinoma - Comparative Analysis
Thymic Carcinoma - Therapeutics under Development by Companies
Thymic Carcinoma - Therapeutics under Investigation by Universities/Institutes
Thymic Carcinoma - Pipeline Products Glance
Clinical Stage Products
Thymic Carcinoma - Products under Development by Companies
Thymic Carcinoma - Products under Investigation by Universities/Institutes
Thymic Carcinoma - Companies Involved in Therapeutics Development
Merck & Co., Inc.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Taiwan Liposome Company, Ltd.
Tiziana Life Sciences Plc
Thymic Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLC-388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thymic Carcinoma - Product Development Milestones
Featured News & Press Releases
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thymic Carcinoma, H2 2016
Number of Products under Development for Thymic Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Thymic Carcinoma - Pipeline by Merck & Co., Inc., H2 2016
Thymic Carcinoma - Pipeline by Novartis AG, H2 2016
Thymic Carcinoma - Pipeline by Onxeo SA, H2 2016
Thymic Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Thymic Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Thymic Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
List of Figures
Number of Products under Development for Thymic Carcinoma, H2 2016
Number of Products under Development for Thymic Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report